Sub Categories

Search

Newsletter

BNP-32 Chemiluminescent EIA Kit Maximize

BNP-32 Chemiluminescent EIA Kit

Human BNP-32 Chemiluminescent EIA Kit (CEK-011-03) is a quantitative in-vitro protocol for analysing concentrations of human brain natriuretic peptide-32 (BNP-32).

More details

CEK-011-03

96 wells

£ 480.00

Human BNP-32 Chemiluminescent EIA Kit

Specificity : Human
Sensitivity : 16.7 pg/ml
Linear Range: 16.7-713.0 pg/ml
Range: 0-10000 pg/ml
Size: 96 tests

Reagents Supplied:
- 96 well immunoplate (1 plate)
- 20x assay buffer concentrate (50ml)
- Standard peptide (1 vial).
- Primary antibody (rabbit anti-peptide IgG) (1 vial).
- Positive control (1 vial).
- Acetate plate sealer (APS), (3 pieces)
- Streptavidin-horseradish peroxidase (SA-HRP) (30μl)
- Substrate solution A (7ml)
- Substrate solution B (7ml)
- Biotinylated peptide (1 vial).
- General protocol (1 book).
- Assay diagram (1 sheet).

Intended Use:
Human BNP-32 chemiluminescent EIA is an in-vitro protocol intended to measure quantitatively the concentrations of human brain natriuretic peptide-32 (BNP-32) present in samples of urine, serum, plasma, culture media, CSF, tissue homogenate and any biological fluid.

Assay Principle:
1. Microwell plate has been pre-coated with secondary antibody and also the non-specific binding sites have been blocked.
2. Secondary antibody is able to bind with the Fc fragment of the primary antibody, the Fab segment is competitively bound by both biotinylated peptides and the peptide standard or the targeted peptide in samples.
3. Biotinylated peptide can then interact with the SA-HRP, which then catalyzes the substrate solution.
5. Luminescence intensity is directly proportional to the amount of biotinylated peptide-SA-HRP complex but inversely proportional to the amount of the peptide in standard solutions or samples.
6. Unknown concentration in samples can then be determined by extrapolation from a standard curve.

Cross Reactivity:
BNP-32 (Human)  100%.
BNP-32 (Rat)  0.04%.
BNP-45 (Rat)  0%.
BNP-26 (Porcine)  0%.
Angiotensin II  0%
Alpha ANP (1-28)(Human, Ovine, Canine)  0%.
Endothelin-1  0%.
VIP  (Rat, Human, Porcine) 0%.

Background:
Brain natriuretic peptide (BNP-32) is a 32 a.a. polypeptide which has been found to be secreted by the ventricles of heart when there is excessive stretching of myocytes. It was first discovered in extracts of porcine brain, whereas within humans it is found to be made in the cardiac ventricles. Elevated levels of BNP 32 and/or NT-proBNP within the blood are useful markers in the diagnosis of heart failure and acute congestive heart failure (CHF). It is also released alongside an NT-proBNP (76 amino acids amino terminal fragment).

References
1. Circulation. (2007) 115 (1): 67-75. Hemodynamic Modulation of Endocardial Thromboresistance. Kapur et al.
2. Vet J. (2008) 178 (1): 85-90. Analytical validation of commercial immunoassays for the measurement of cardiovascular peptides in the dog. Schellenberg S, et al.
3. J Vet Intern Med. (2008) 22 (5): 1118-23. Evaluation of NT-pro BNP and CT-ANP as markers of concentric hypertrophy in dogs with a model of compensated aortic stenosis. Hori Y, et al.
4. Vet J. (2008) 178 (1): 85-90. Analytical validation of commercial immunoassays for the measurement of cardiovascular peptides in the dog. Schellenberg S, et al.
5. Clin Chem. (2011) 57 (6): 864-73. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Tonne JM et al.
6. J Cardiovasc Pharmacol. (2008) 52 (3): 253-61. Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure. Bartha et al.

Special Offers